State Legislative Issues

California law surrounding innovative new biologic and biosimilar medications has returned for the 2015-2016 session. 

Because of the complexity of creating these drugs, it is virtually impossible to create identical “generic” products of biologics. Instead, biologics have what are called biosimilar or interchangeable biological products that meet varying degrees of similarity. This is especially important today with the introduction of interchangeable biologics into state markets continuing to grow closer. 

On October 1, 2014, the state began to implement the long-awaited Uniform Prescription Drug Prior Authorization Request Form.  Certain health plans in California will be required to implement the form, as well as abide by new timelines and notification procedures, when processing prior authorization requests for prescription drug benefits.

California and many other states across the country are focusing increased attention on chronic disease screening, prevention and awareness including such rheumatic diseases as arthritis. These public policy proposals seek to raise awareness of the significance of the health issue and call for a coordinated and comprehensive response. Treatments for these conditions continue to improve with significant new research and better patient options. At the same time, the costs associated with these conditions grow. California proclaimed May as Arthritis Awareness Month, and September has become Pain Awareness Month.  CRA partners with patient advocacy organizations, physicians and other key partners to ensure that prevention, screening and awareness around rheumatic diseases grows and patients can access the lifesaving treatments that they need.